Archive: Raymond J. March
The Mental Health Crisis and FDA Hurdles
Despite promising research, the potential for MDMA, and other psychedelic drugs to help treat mental illnesses depends on the a pending FDA decision
Favor Local Action to Combat the Coronavirus
The government’s tendency to take drastic action and achieve lackluster results suggest that local efforts to mitigate crises might be more successful.
Are More Vaping Bans Coming Soon? Let’s Hope Not!
To truly “prioritize children, family, and the public health,” we should consider telling the FDA to stop regulating e-cigarettes cold turkey.
Only Markets Can Alleviate Drug Shortages
The most onerous barriers to alleviating drug shortages are regulations.
New FDA Commissioner, Same FDA Problem
The most beneficial regulations the new FDA commissioner can implement, by far, will be restrictions on the FDA itself.
Telemedicine Continues to Reach New Heights
Thankfully, telemedicine provides solutions for many who might otherwise suffer healthcare-access woes.
Breakthrough Alzheimer’s Drug Puts FDA’s Drug-Approval Process into Question
Peer-reviewed research and many case studies highlight weaknesses in the FDAs drug approval approach.
Is Right-to-Try Legislation a Bust? Time for a Second Opinion.
While right-to-try is currently underused, efforts to expand its role in helping those with terminal illnesses are underway.
Banning E-Cigarette Sales Will Do More Harm than Good
Efforts to ban vaping are extremely unlikely to succeed and may push consumers toward harmful alternatives.
How Government Prolonged the Lobotomy
While the lobotomy offers a cautionary tale of medicine gone astray, it should also provide a cautionary tale of the harmful consequences of state-assisted health policies.
New Study Finds FDA in Contempt of the U.S. Constitution
The vast majority of agency regulations were passed by “low-level officials and employees with no authority to issue rules.”